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• A series of polycyclic lactones containing 1,4-dioxine core was synthesized.  
• The series a exhibited KRasWnt inhibition while the b series was inactive. 
• Lactone 2a presents the best KRas activity profile on SW480 cell type. 
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Abstract. An efficient four-step synthesis of tetracyclic lactones from 1,4-benzodioxine-2-carboxylic 
acid was developed. Ellipticine derivatives exhibit antitumor activity however only a few derivatives 
without carbazole subunit have been studied to date. Herein, several tetracyclic lactones were 
synthesized and biologically evaluated. Several compounds (2a, 3a, 4a and 5a) were found to be 
inhibitors of the Kras-Wnt pathway. The lactone 2a also exerted a potent inhibition of Tau protein 
translation and was shown to have capacity for CYP1A1-bioactivation. The results obtained are further 
evidence of the therapeutic potential of tetracyclic lactones related to ellipticine. Molecular modeling 
studies showed that compound 2a is inserted between helix 3 and 4 of the KRas protein making 
interactions with the hydrophobic residues Phe90, Glu91, Ile9364, Hie94, Leu133 and Tyr137and a 






Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole, 1), is a planar tetracyclic alkaloid that presents an 
interesting cytotoxic activity attributable to multiple mechanisms of action. However, the therapeutic 
applications of ellipticine remain limited because of the large number of side effects [1]. Interest in the 
ellipticine pharmacophore has attracted the attention of many research groups because of their multiple 
biological activities [2] and especially for their capacity to inhibit cancer cell growth [3].  
Previously, we have reported on ellipticine derivatives in which the indole nucleus has been replaced by 
1,4-benzodioxine as interesting bioactive compounds, but their mechanism of action was not confirmed 
[4]. In this study, we report the preparation of ellipticine derivatives containing the 1,4-benzodioxine 
nucleus and a lactone replacing the pyridine system. These structural changes and the presence of 
different substituents make these compounds interesting and promising antitumor candidates.   
 
 
Figure 1. Ellipticine and analogues 
 
Compounds containing a 1,4-benzodioxine subunit have received significant attention as a useful 
scaffold in chemical and pharmaceutical research. The lactones 2a-7a and 2b-7b were prepared in four 
steps from 1,4-benzodioxin-6-carboxylic acids using previously published methodology to prepare small 
quantities for biological investigations [5]. In this work, we have refined the methodology to enable 
multigram scale synthesis (Scheme 1) and reported on the antiproliferative activity of these compounds 
and investigations to understand their mechanism of action including KRas/Wnt inhibition, angiogenesis 
inhibition and cytochrome P450 1A1 (CYP1A1) bioactivation. 
 
2. Results and discussion 
2.1. Chemistry 
Carboxylic acids 8a-b, hydroxyacids 9a-e, tricyclic lactones 10a-e and substituted dienes 11a-e were 
prepared on a gram scale by the procedures previously described by us without major changes [5]. The 
yields with which these compounds were obtained are indicated in Scheme 1 and are practically in the 
same order as those reported. Then the last stage involves Diels-Alder condensation of the dienes 11a-e 
with 2(5H)-furanone catalysed by BF3.Et2O that leads to a mixture of tetracyclic lactones a and b 
depending on the position of the carbonyl group regarding the long alkyl side chain (Rʹ). Both positional 
isomers (2a-7a and 2b-7b) were separated by column chromatography. Likewise lactones 6a-b were 
obtained by Diels-Alder cycloaddition of the diene 11c and the 2(5H)-thiofuranone following the same 
Diels-Alder methodology. In this work the amount of 2(5H)-furanone or 2(5H)-thiofuranone added 
doubled, the amount of solvent was reduced and the reaction time was lengthened compared to the first 
work described [5]. With these changes, the yields of both isomers are significantly increased (for 2a, 
the yield has increased from 20 to 33% and for 2b from 24 to 39%; 3a had an improvement of 19 to 
30% and 3b of 25 to 48%; 4a of 21 to 36% and 4b of 25 to 40%; 5a of 19 to 31% and 5b of 23 to 43%; 
6a was obtained in 20% and now in 39% and 6b has passed from 22 to 46%; 7a had an improvement of 
22 to 37% and 7b of 24 to 45%). The structures of the prepared compounds are supported by 1H and 13C 
NMR spectra. 
 
Reagents and conditions: i: 1) LDA/THF, 2) R’CHO. ii: PTSA/toluene. iii: 1) Li-CH3, (CH3)3SiCl, 2) NH4Cl. iv: 
2(5H)-furanone or 2(5H)-thiofuranone /BF3.Et2O  
 
Scheme 1. Synthesis of tetracyclic lactones  
 
2.2. Biological activity profiling. All the title compounds 2a-7a and 2b-7b were subjected to biological 
tests. While many ellipticine analogues exert anticancer activity by inhibition of topoisomerase I and/or 
II it appears that tetracyclic lactone congeners do not target these enzymes or DNA for antiproliferative 
activity [5]. To study the biological properties we collaborated with Eli Lilly laboratories within the 
OIDD program [6] and the results are shown in Tables 1-5.  
 
2.2.1. KRas Inhibition. KRas mutations are involved in the development of many human tumors. 
Progression to colorectal cancers (CRC) requires a second event such as an activating KRas mutation, 
which is triggered by undefined interactions between the Wnt signalling pathways and the KRas protein 
[7]. The KRas synthetic lethal phenotypic assay measures survival of CRC cells carrying mutations that 
activate both Wnt and KRas signaling relative to those with other driver mutations [7]. The measurement 
of ATP is an accepted method to estimate the number of viable cells. Human CRC cell lines with KRas 
mutations (DLD‐1, HCT116, and SW480) were used to test the effect of the tetracyclic lactones on cell 
proliferation in vitro [8]. 
The results showed that compounds 2a, 3a, 4a and 5a exerted dose-dependent inhibition of CRC cells 
while compounds 2b, 3b, 4b, 5b, 6b, and 7b generally were less potent active (see Table 1). Interestingly, 
a limited inhibitory effect was observed at the lowest dose of 2a in HCT116 cells, but it increased 
substantially in glycogen synthase kinase-3 GSK3- inhibitor HCT pretreated cells. This result indicates 
an effect on the Wnt pathway at low dose (0.2 M) but not at the higher doses investigated (2 and 20 M). 
The data also reveals that, in general, the compounds presenting the carbonyl group of lactone on the same 
side as the long alkyl chain (series a) are more potent compounds than when it is on the side of the methyl 
group (series b) (see position of R', Scheme 1). 
Table 1. Basal viability of [1,4]-benzodioxine analogues in a panel of colorectal cancer cells lines using ATP assay 
 
The length of alkyl chain (4, 5 or 6 carbons (2a, 3a and 4a)) modifies cytotoxic activity very little. 
Likewise, the introduction of halogen on the alkyl chain (5a) produces only slight modifications in the 
activity, while the change from lactone to thiolactone leads to a pronounced decrease in potency (6a and 
6b). Finally, the introduction of a methoxyl group as a substituent of the first aromatic ring of the 






























0.2 17 12 20 11 21 16 7 -40 13 10 15  
2 73 14 64 21 58 18 62 4.4 9 10 16  
20 138 14 86 40 86 12 63 55 22 21 19 -10.7 
DLD-1 
 
0.2 17 -29 60 -11 14 29 30 0.4 -9 -10 -17  
2 65 6 63 17 50 49 45 0.4 7 6 16  
20 91 41 120 40 112 -15 76 20 90 14 73 -3.9 
HCT116  
0.2 5 39 20 -9 12 -3 33 2 -17 -10 -14  
2 66 7 62 12 60 7 56 9.5 10 2.9 7.9  





0.2 67 -58 5 44 52 26 15 12 -29 -106 52  
2 63 0.4 59 28 69 10 58 20 -4 -5.6 8  
20 80 2 66 31 62 2 53 28 18 3.4 6  
tetracyclic lactone (at the C-7 position) also produces a marked loss in cytotoxicity (7a and 7b) 
attributable to that the substituent difficult the binding to the active site of the target. 
 
2.2.2. Angiogenesis inhibition. Angiogenesis and vasculogenesis facilitates blood vessel sprouting and 
tube formation, processes which can be modified using vascular disrupting agents (VDAs) that cause 
rapid collapse and shut down of established cancer blood vessels leading to regional tumor ischemia and 
necrosis [9]. Often inhibitors of angiogenesis bind the extracellular domain of vascular endothelial 
growth factor (VEGF) receptor-2 [10] or the specialized ligands VEGF-A, VEGF-C and VEGF-D [11]. 
Monoclonal antibodies targeting endothelial factors have been studied and approved by the FDA for the 
treatment of several tumors [12]; however, it should be noted that small molecules with the same 
therapeutic use are still not medically used.  
The results showed that compounds 2a, 3a, 4a and 5a (a series) possessed a high antiangiogenic activity 
on tube area but not on nuclear count, demonstrating selectivity of these compounds, while the 
compounds in the b series (2b, 3b, 4b, 5b, 6b, and 7b) were inactive in both assays (Table 2). In 
addition, side alkyl chains with more than 5 C lead to inactive compounds. Compounds (2a, 3a, 4a and 
5a could be of interest for the reduction of angiogenesis in endothelial tube formation without causing 
antiproliferative activity. As observed in the KRas inhibition assay, compounds possessing an alkyl 
substituent on the same side as the carbonyl group of the lactone were also the most potent analogues as 
antiangiogenic inhibitors.  
Table 2. Antiangiogenic data from endothelial tube and nuclear tests 
Comp.  Angio TubeArea 
(IC50 M) 
 Angio NucArea 
(IC50 M) 
2a 1.5±0.2 >10 
2b - - 
3a 1.3±0.1 >10 
3b >10 >10 
4a 1.0±0.2 >10 
4b - - 
5a 0.7±0.2 >10 
5b >10 >10 
6a >10 >10 
6b inactive inactive 
7a inactive inactive 
7b inactive inactive 
 
2.2.3. Cellular Cycle Phase. In general, the timing of key cell-cycle phase transitions is controlled by 
cell-cycle checkpoints, which prevent cells from advancing inappropriately or prematurely to the next 
phase of the cell cycle. A particularly critical checkpoint occurs in G2/M and governs cellular 
commitment to enter cytokinesis. The results suggests that compounds 2a, 3a, 4a and 5a have an effect 
on cell cycle progression of HeLa cells on 2N, 4N and MI due to arrest of cells (Table 3), while 
compounds 6a and 7a showed no activity at the concentrations tested. All b isomers were also inactive. 
 
Table 3. Cellular Cycle Phase on Hela 
 
Comp. Hela CellCyc  
2N (IC50 M) 
Hela cellCyc  
4N (EC50 M) 
 Hela CellCyc  
MI (EC50 M) 
 Hela CellCyc  





2a 2.2±0.3 2.0±0.1 2.1±0.1 1.7±0.2 >10 >10 
3a 1.8±0.2 1.6±0.3 1.4±0.1 1.0±0.2 >10 >10 
4a 2.1±0.1 2.0±0.1 >10 1.8±0.3 >10 >10 
5a 1.5±0.1 1.4±0.1 1.3±0.2 0.6±0.2 >10 >10 
6a >10 >10 >10 >10 >10 >10 
7a >10 >10 >10 - >10 >10 
7b >10 >10 >10 - >10 >10 
       
It is worthy of note that compounds 7a and 7b containing a methoxy group on the aromatic ring are 
surprisingly inactive in several cytotoxic tests while the methoxylated derivatives of ellipticine showed 
high cytotoxicity [13]. 
 
2.2.4. Wnt pathway activation. Osteoporosis is a silent disease that weakens the bones over time and 
increases the risks of fractures. The mechanism of bone loss is not yet well understood, but the disorder 
arises from an imbalance in the formation of new healthy bones and the decrease and resorption of bone 
tissue. The imbalance is partly triggered by a decrease of bone protein matrix and mineral content [14a]. 
The aim of a Wnt pathway activator is to discover compounds to increase bone development and 
especially slow down osteoporosis. In this regard, a phenotypic bone formation assay is useful to 
evaluate compounds for their ability to differentiate murine C2C12 cells, which possess multi-lineage 
potential and an osteoblast-like phenotype through -catenin-dependent stimulation of alkaline 
phosphatase activity [14b]. Compounds of therapeutic interest increase osteoblast formation in rodent 
and human cellular assays through a non-glycogen synthase kinase (GSK) mechanism. Tetracyclic 
lactones 2a, 3a, 4a and 5a displayed interesting activity by activation of the Wnt pathway through 
stimulation of alkaline phosphatase activity but not -catenin (Table 4). The lactones of the series a with 
side chains greater than 5 carbon atoms were practically inactive. The compounds of the b series did not 
show activity either. 
 








2a 6.7±1.9              >20 
3a 6.3±1.5 - 
4a 7.6±1.1 >20 
5a 8.2±0.9 >20 
6a           >10  >10 
7a           >10            >10 
7b           >10            >10 
 
2.2.5. Other biological properties [15]. The tau protein is related to neuroprotection and Alzheimer’s 
disease. This protein acts in vivo to induce tubulin assembly and stabilize microtubules, and the activity 
may be necessary but not sufficient for neuronal morphogenesis. Lactone 2a so do 3a and 4a showed 
important inhibition of Tau protein translation at 40 M concentration. In addition, 2a presents 
inhibition of other haplotypes such as AngptI8 (inhibit lipoprotein lipase and decrease plasma 
triglyceride) APOC3 (decrease of triglycerides), Nav1.7 (antinociceptive activity related to sodium ion 
channel) [15] and PCSK9 (cholesterol-lowering drugs [16]) at 40 M (Table 5).  
 














2a 92 93 89 76 95 
2b 8 15 34 -62 15 
3a 88 89 78 74 69 
3b - - - - - 
4a 77 86 75 -25 75 
4b 11 24 17 -9 -7 
5a 56 67 67 0             35 
5b 35 37 17 -32 40 
6a 20 31 21 -10 30 
6b 30 27 7 -2 -4 
7a 60 59 38 22 42 
7b 23 34 12 -12 -7 
 
2.2.6. Activity under hypoxic conditions and 3D cell cultures  
Solid tumors are often characterized by areas with inadequate blood supply, lower oxygen tension and 
nutrient supply. Tumor cells distant from the existing blood vascular capillaries (> 100 µm) often 
become hypoxic and resistant to both radio and chemotherapy. It is also known that hypoxia contributes 
to the progression of a more aggressive phenotype via activation of several genes including induction of 
hypoxia-inducible factor 1-alpha (HIF1-α) and subsequently VEGF that contributes to angiogenesis [17-
20]. 
As compounds 2a and 4a were consistently shown to produce a biological response in all assays 
investigated and possessed antiangiogenic properties (Table 2), these were selected for interrogation in 
HT29 colon cancer cells, which harbor wild-type KRas protein, under both normoxic and hypoxic 
conditions. Both compounds 2a (HCR = 0.24) and 4a (HCR = 0.15), showed a small loss of potency 
under hypoxic conditions, in contrast to irinotecan which was unaffected by the lower oxygen tension 
(HCR = 1.12). The effect of 3a and 4a in HT29 cells was less effective in oxygen-deprived environment 
versus normoxic cells, showing more resistance in hypoxic conditions as it happens to the majority of 
antitumor agents. 
 
Table 6: Growth inhibition of compounds 2a and 4a against HT29 colon cancer cells under normoxic and hypoxic conditions 
Compound 
 
Normoxia IC50 ± SD (µM) Hypoxia IC50 ± SD 
 (µM) 
HCR: IC50 norm/ IC50 hypoxic 
2a  1.73 ± 0.25 7.33 ± 1.60  0.24  
4a  1.33 ± 0.22 8.93 ± 1.27       0.15 














































Figure 2: IC50 values and hypoxic cytotoxicity ratio (HCT) for 2a, 4a and irinotecan were evaluated under normoxic and 
hypoxic conditions in adherent HT29 cells using MTT assay. Each value represents the mean of at least three independent 
experiments 
 
2.2.7. CYP1A1 bioactivation  
The natural product ellipticine (1) exerts its antiproliferative activity in part via CYP1A1 bioactivation 
leading to a metabolite capable of covalently binding DNA. CYP1A1 has been shown to be 
differentially overexpressed in CRC while its expression in normal surrounding epithelia is relatively 
low [21]. Given scaffold similarity of the lactones presented in this study with ellipticine, interrogation 
of their potential for CYP1A1 bioactivation were assessed in the CHO/CHO1A1 isogenic cell line pair. 
Analogue 2a and the thiofuranone analogue 4a were chosen as a suitable pair for this investigation. 
Lactone 2a was found to be 3.7-fold more antiproliferative in CHO1A1 cells compared with parental 
CHO cells while the thiofuranone 4a had much lower potentiation effect in the presence of CYP1A1 
(Table 7). Ellipticine was shown to be approximately 15-fold more potent in CHO1A1 cells, which is in 
accordance with previous studies that have confirmed CYP1A1 as a bioactivating enzyme responsible 
for generating a metabolite capable of damaging DNA via adduct formation [22]. 
 

















Irinotecan in monolayered HT29
Hypoxia n=4 Normoxia n=5
Compound  CHO CHO1A1 PF 
2a 1.48±0.13a 0.4±0.1 3.7 
4a 1.52±0.13 2.6±0.7 0.6 
Ellipticine (1) 0.02±0.05 0.0193±0.005 15.6 
 aIC50 values for 2a, 4a and ellipticine were derived from  
 at least three independent experiments 
 
3. Molecular Modeling Studies 
Compound 2a (L2a) was selected as a representative member of the diverse benzodioxine analogues of 
the most active series a described above for the determination of its most probable binding site to KRas. 
To achieve this objective, we thoroughly explored the conformational space of the KRas-L2a system 
performing a docking procedure over the five different predicted binding sites of the KRas protein [23, 
24], (Figure 3) as explained in the experimental section.  For each binding site, we selected the five best 
docked poses. Then, the twenty-five complexes were prepared and subjected to 20 ns of molecular 
dynamics (MD) for an initial analysis. The total binding free energies calculated by both MMPBSA and 
MMGBSA approaches were plotted as a function of the trajectory length to determine the convergence 
behavior of the different complexes. Table S1 of Supporting Information contains all the information 
extracted from the global analysis process.  
Visual inspection of the MD trajectories allows us to classify the different complexes in four different 
groups. The first one corresponds to those systems where the ligand moves away from the protein 
during the 20 ns of MD (Case [1] and no binding is observed (Table S1 and Figures S7, S8, S9 and 
S16). The second group corresponds to complexes with bad convergence and low values of ΔGb (Case 
[2] in Table S1 and Figures S10, S15 and S17).  The third one is composed by those complexes that 
present good convergence only for the last 5 ns, but with |ΔGb| smaller than 25 kcal/mol (Case [3] in 
Table S1 and Figures S2, S5, S12 and S13). Finally, the last group corresponds to those complexes that 
present good convergence during more than 5 ns, but with |ΔGb| smaller than 25 kcal/mol (Case [4] in 
Table S1 and Figures S1, S3, S4, S6, S11 and S14). All complexes included in these four groups 
(Colored red in Table S1) were discarded from future analysis and only the remaining eight complexes 
which showed better convergence and |ΔGb| values greater than 25 kcal/mol were retained (Yellow, 
brown and green colors in Table S1).  
In a second step, the length of the MD of the eight best complexes was extended to 100 ns to permit a 
better-induced fit of the protein. In this step, only one structure was rejected because the binding energy 
for the last 5 ns was worse than -25 kcal/mol (Brown color in Table S1 and Figure S18). Thus, to 
distinguish between the remaining seven poses the length of the MD was extended to 300 ns. Now, 
poses 1 and 3 of pocket 1 and poses 1 and 3 of pocket 2 were discarded because of their no-binding or 
low binding energy (Yellow color in Table S1 and Figures S19 to S22). Finally, for the three remaining 
poses (Green color in Table S1) the length of the MD was extended to 700 ns. Pose 4 of pocket 1 was 
clearly stable during the last 300 ns; however, it was discarded because of its worse binding energy as 
compared to those of the remaining two poses (Figure S23). The two remaining poses present very 
similar (both PB and GB) final binding energies (Green color in Table S1 and Figures S24 and S25), 
with both involving docking at pocket P3. However, a visual inspection of the final structures (Figure 
S26) shows that they are not located in the P3 pocket but inserted between helix 3 and 4, a binding 
site not previously described until now, with their carbonyl groups pointing in opposite directions. Thus, 
considering all this information, we can conclude that the most probable binding mode of compound 2a 
corresponds to pose 1 of pocket 3, as in this structure the carbonyl group presents a hydrogen bond with 
the protein that does not appear in the other structure (pose 4 of pocket 3). This finding explains the fact 
that compounds of series b, which share the carbonyl group at the opposite side of the aliphatic moiety, 
present a very low activity.   
 
 
Figure 3. The most relevant structural motifs of the KRas protein are indicated. The location of the four 
allosteric ligand-binding sites is shown in colored mesh (p1 to p4) and the P3b allosteric site is located between 
L5, L7 and 5 motifs. The predicted binding site of the studied compound is located between the 3 and 4 
helix. The GTP cofactor is represented by sticks 
 
Residues of KRas contributing to the binding free energy of the selected KRas-L2a complex were 
analyzed during the last 100ns of MD, and the average values are reported in Figure S26. A 3D 
representation of the binding site and the interacting residues is shown in Figure 3. From this figure, it 
can be seen that the ligand is inserted in a deeper pocket, where the fused rings interact with the 
hydrophobic residues Phe90, Glu91, Ile9364, Hie94, Leu133 and Tyr137. In addition, the complex 
establishes one stable hydrogen bond (HB) with the protein, between the carbonyl oxygen of the ligand 
and the charged residue Arg97.  
Finally, we introduced a methoxy group as a substituent of the first aromatic ring of the tetracyclic 
lactone (at C-7 position, compound 7a) to compare its stability with the original 2a ligand. As expected, 
both the MMPBSA and MMGBSA approaches suggest that the substituted compound has a smaller 
binding energy than the original one although the difference is small; 0.8 kcal/mol and 0.2 kcal/mol for 
the MMGBSA and MMPBSA methods, respectively. The convergence of ΔGb is shown in figure S28 
(supporting information). The final structures of both compounds are displayed in figure S29 
(supporting information), in which we can see that the position of the 7a modified compound is 




Figure 4. A Spatial representation of the complex KRas-L2a for the selected structure. a) Description of 
the binding pocket with the ligand. b) Spatial representation of the most important residues that interact 
with the ligand. c) The KRas-L2a complex showing the hydrogen bonds in green 
 
4. Conclusion 
A series of linear 1,4-benzodioxine lactones related to ellipticine were investigated and several 
compounds were synthesized from 1,4-benzodioxine-2-carboxylic acid in 4 steps. A clear conclusion is 
that lactones possessing an alkyl chain on the same side as the carbonyl group of the lactone (2a, 3a, 4a, 
5a and 6a, series a) are more active than the corresponding positional isomers with the alkyl chain on 
the opposite side of the carbonyl (series b). Regarding the length of the alkyl group, in general, the 
butyl, pentyl and hexyl chains were the best. These tetracyclic lactones of the series a have shown an 
interesting profile of biological activities. It should be noted that the introduction of a methoxyl group 
into the aromatic ring of lactone 3a causes a considerable loss of activity (7a) as does the introduction of 
a sulfur atom (6a). 
Analogue 2a possessing a butyl side chain exhibited an interesting biological profile. It exhibited 
activity in the KRas-Wnt synthetic lethal primary single point assay, exhibited both antiangiogenic and 
antiproliferative properties while potentiation of anticancer effect is possible in the presence of CYP1A1 
which is known to be expressed in a number of cancer types including colorectal carcinoma (CRC) [25]. 
As such, lactone 2a represents a good starting point for further medicinal chemistry aimed at generating 
novel agents to probe the colorectal carcinoma microenvironment.  
 
5. EXPERIMENTAL SECTION 
5.1. Chemistry 
Melting points (mp) were determined on a Gallenkamp-apparatus (MFB-595010M) with interior 
thermometer using open capillary tubes and are reported after correction. IR spectra were obtained using 
FTIR Perkin-Elmer 1600 Infrared Spectrophotometer. 1H and 13C NMR spectra were recorded on a 
Varian Gemini-300 and 400 MHz (75.5 and 100 MHz respectively for 13C). Chemical shifts are reported 
in parts per million (ppm) relative to the central peak of the used solvent: CDCl3 (, 7.26 (H) and 77.16 
(C)), CD3OD (, 3.31 (H) and 49.45 (C)), DMSO-d6 (, 2.49 (H) and 39.51 (C)) as internal standards. 
The following abbreviations are used for the proton spectra multiplicities: bs, broad signal, s, singlet, d, 
doublet, t, triplet, q, quadruplet, m, multiplet. Coupling constants (J) are reported in Hertz (Hz). The 
reactions were monitored by thin-layer chromatography (TLC) analysis using silica gel (60 F254, 
Merck) plates and compounds were visualized by UV irradiation. Column chromatography was 
performed with silica gel 60 (230-400 mesh, 0.040-0.063 mm) and automatic column chromatography 
was performed with a CombiFlash Rf system with UV-vis (PN 68-5230-008) detector and RediSep Rf 4 
and 12 g silica gel column. High-resolution mass spectra (HRMS) were performed on a LC/MSD-TOF 
(2006) (Agilent technologies) at the University of Barcelona (Serveis Científico-Tècnics UB). All 
reagents were of high quality or were purified before use. All organic solvents were of analytical grade 
or were purified by standard procedures before use. 
The hydroxyacids (9a-9e), lactones (10a-10e) and furans (11a-11e) have been prepared according to the 
procedure described previously [5] but operating on a larger scale (6-12 g). The yields obtained are 
indicated in Scheme 1. 
 
5.1.1. Preparation of lactones (2a-7a and 2b-7b) via Diels-Alder cycloadditions of the furans (11a-
e). General procedure. 2(5H)-furanone (30 mmol) or 2(5H)-thiofuranone (30 mmol) and BF3.etherate 
(catalytic amount) were added to the corresponding diene 11a-11e (10 mmol) free of solvent at room 
temperature. The obtained mixture was then stirred in a hermetically closed flask on a pre-heated bath at 
90 ºC for 6 h. The crude product was purified with silica gel column chromatography and hexane/ethyl 
acetate was used as eluent. Two positional isomers were obtained, which were accurately separated and 
identified. 
 
5.1.1.1. 11-Butyl-4-methyl-1-oxo-3(H)-isobenzofuro[5,6-b][1,4]benzodioxine (2a). Following the 
general procedure described above for the preparation of polycyclic lactones and using as starting 
materials the diene 11a (3.4 g, 13.9 mmol), and the lactone, the lactone 2a (1.40 g, 4.43 mmol) was 
obtained. The crude product was purified by silica gel column chromatography, using hexane/ethyl 
acetate 97/3 as eluent. The lactone was obtained as a white solid in 33% yield. The isomer 2b (1.70 g, 
5.37 mmol) was obtained in 39% yield, by using the same eluent. Analytical data for 2a: mp 122-125 ºC 
(hexane/ethyl acetate). IR (KBr)  (cm-1): 1750 (C=O), 1258 (Ar-O), 1098 (C-O). RMN-1H (CDCl3, 200 
MHz) (ppm): 0.96 (t, J = 7.0 Hz, 3H, CH3), 1.25-1.50 (m, 2H, CH2CH3), 1.51-1.60 (m, 2H, 
CH2CH2CH3), 2.17 (s, 3H, CH3), 3.05 (t, J = 7.0 Hz, 2H, CH2), 5.09 (s, 2H, CH2O), 6.84-6.90 (m, 4H, 
Ar). 13C NMR (CDCl3, 75.5 MHz) (ppm): 10.7 (CH3), 13.9 (CH3), 22.5 (CH2), 23.2 (CH2), 32.1 (CH2), 
67.6 (CH2), 116.3 (CH), 116,5 (CH), 116.6 (C), 117.2 (C), 123.9, and 124.5 (CH), 129.3 (C), 140.7, and 
141.0 (C), 141.4, and 142.0 (C), 144.4 (C), 169.0 (C). Anal. Calcd. for C19H18O4: C 73.53%; H 5.85%. 
Found: C 73.48%; H 5.91%. 
 
5.1.1.2. 4-Butyl-11-methyl-1-oxo-3(H)-isobenzofuro[5,6-b][1,4]benzodioxine (2b). mp 153-155 ºC 
(ethyl acetate). IR (KBr)  (cm-1): 1743 (C=O), 1270 (Ar-O), 1160 (C-O). 1H NMR (CDCl3, 200 MHz) 
(ppm): 0.95 (t, J = 7.0 Hz, 3H, CH3), 1.25-1.45 (m, 2H, CH2CH3), 1.45-1.62 (m, 2H, CH2CH2CH3), 
2.55 (s, 3H, CH3), 2.57 (t, J = 7.0 Hz, 2H, CH2), 5.09 (s, 2H, CH2O), 6.68-6.95 (m, 4H, Ar). 
13C NMR 
(CDCl3, 75.5 MHz) (ppm): 9.39 (CH3), 13.8 (CH3), 22.7 (CH2), 25.5 (CH2), 31.1 (CH2), 67.8 (CH2), 
116.4, and 116.3 (CH), 117.8 (C), 121.8 (C), 123.8 (C), 123.9, and 124.4 (CH), 141.3 (C), 141.5 (C), 
144.4 (C), 170.7 (C). Anal. Calcd. for C19H18O4: C 73.53%; H 5.85%. Found: C 73.69%; H 5.89%. 
 
5.1.1.3. 4-Methyl-11-pentyl-1-oxo-3(H)-isobenzofuro[5,6-b] [1,4]benzodioxine (3a). A mixture of the 
diene 11b (3.5 g, 13.6 mmol) and the lactone was treated following the general procedure to prepare 
lactones as described above. The crude product was purified by silica gel column chromatography, using 
hexane/ethyl acetate 98/2 as eluent, obtaining the lactone 3a as a white solid in 30% (1.4 g, 4.0 mmol) 
yield. The isomer 3b was obtained in 48% yield (2.18 g, 6.5 mmol) using hexane/ethyl acetate 99/1 as 
eluent. Analytical data for 3a mp 108-110 ºC (ethyl acetate). IR (KBr)  (cm
-1): 1750 (C=O), 1260 (Ar-
O), 1105 (Ar-O). 1H NMR (CDCl3, 300 MHz) (ppm): 0.83-0.89 (m, 3H, CH3), 1.33-1.45 (m, 4H, 
(CH2)2, 1.50-1.65 (m, 2H, CH2), 2.18 (s, 3H, CH3), 3.05 (t, J = 7.5 Hz, 2H, CH2), 5.05 (s, 2H, CH2O), 
6.69-7.02 (m, 4H, Ar). 
13C NMR (CDCl3, 75.5 MHz) (ppm): 10.8 (CH3), 14.0 (CH3), 22.4 (CH2), 23.3 
(CH2), 29.4 (CH2), 31.4 (CH2), 67.5 (CH2), 116.4 and 116.4 (CH), 116.8 (C), 117.2 (C), 124.0 and 124.8 
(CH), 129.3 (C), 140.7 and 141.2 (C), 141.8 and 142.2 (C), 144.9 (C), 170.6 (C). Anal. Calcd. for 
C20H20O4: C 74.06%; H 6.21%. Found: 74.31%; H 6.44%. 
 
5.1.1.4. 11-Methyl-4-pentyl-1-oxo-3(H)-isobenzofuro[5,6-b][1,4]benzodioxine (3b). mp 145-146 ºC 
(ethyl acetate). IR (KBr)  (cm-1): 1742 (C=O), 1264 (Ar-O), 1140 (Ar-O). 1H NMR (CDCl3, 200 MHz) 
(ppm): 0.83-0.99 (m, 3H, CH3), 1.19-1.38 (m, 4H, CH2), 1.42-1.58 (m, 2H, CH2), 2.55 (s, 3H, CH3), 
2.53 (t, J = 7.5 Hz, 2H, CH2), 5.07 (s, 2H, CH2O), 6.60-6.93 (m, 4H, Ar). 
13C NMR (CDCl3, 50.3 MHz) 
(ppm): 9.4 (CH3), 14.0 (CH3), 22.5 (CH2), 26.0 (CH2), 28.5 (CH2), 31.7 (CH2), 67.5 (CH2), 116.2 and 
116.5 (CH), 117.5 (C), 121.7 (C), 123.9 (C), 124.0, and 124.4 (CH), 141.3 (C), 141.7 and 141.8 (C), 
144.2 (C), 170.9 (C). Ana.l Calcd. for C20H20O4: C 74.06%; H 6.21%. Found: C 74.32%; H 6.09%. 
 
5.1.1.5. 11-Hexyl-4-methyl-1-oxo-3(H)-isobenzofuro[5,6-b] [1,4]benzodioxine (4a). The diene 11c 
(3.1 g, 11.4 mmol) and the lactone were treated following the general procedure to prepare lactones as 
described above to obtain lactone 4a. The crude product was purified by silica gel column 
chromatography, using hexane/ethyl acetate 98/2 as eluent to obtain the lactone as a white solid in 36% 
yield (1.39 g, 4.09 mmol). The isomer 4b (1.55 g, 4.56 mmol) was obtained in 40% yield using the same 
eluent. Analytical data for 4a: mp 131-133 ºC (ethyl acetate). IR (KBr)  (cm
-1): 1760 (C=O), 1252 (Ar-
O), 1110 (Ar-O). 
1H NMR (CDCl3, 200 MHz) (ppm): 0.82-0.90 (m, 3H, CH3), 1.18-1.42 (m, 6H, 
CH2)3), 1.54-1.64 (m, 2H, CH2), 2.14 (s, 3H, CH3Ar), 3.04 (t, J = 7.5 Hz, 2H, CH2), 5.04 (s, 2H, 
CH2O), 6.72-7.00 (m, 4H, Ar). 
13C NMR (CDCl3, 50.3 MHz) (ppm): 10.7 (CH3), 14.3 (CH3), 22.7 
(CH2), 23.3 (CH2), 29.0 (CH2), 30.0 (CH2), 31.5 (CH2), 67.4 (CH2), 116.0, and 116.3 (CH), 116.6 (C), 
117.3 (C), 124.0 and 124.5 (CH), 129.3 (C), 140.7 and 140.8 (C), 141.3 and 142.0 (C), 144.5 (C), 170.7 
(C). Anal. Calcd. for C21H22O4: C 74.54%; H 6.55%. Found: C 74.46%; H 6.62%. 
 
5.1.1.6. 4-Hexyl-11-methyl-1-oxo-3(H)-isobenzofuro[5,6-b][1,4]benzodioxine (4b). mp 149-150 ºC 
(ethyl acetate). IR (KBr)  (cm-1): 1759 (C=O), 1260 (Ar-O), 1135 (Ar-O). 1H NMR (CDCl3, 200 MHz) 
(ppm): 0.80-0.89 (m, 3H, CH3), 1.20-1.40 (m, 6H, (CH2)3), 1.43-1.64 (m, 2H, CH2), 2.43 (s, 3H, 
CH3C11), 2.40 (t, J = 7.5 Hz, 2H, CH2), 5.10 (s, 2H, CH2O), 6.81-6.97 (m, 4H, Ar). 
13C NMR (CDCl3, 
50.3 MHz) (ppm): 9.4 (CH3), 14.2 (CH3), 22.7 (CH2), 26.0 (CH2), 28.9 (CH2), 29.3 (CH2), 31.4 (CH2), 
67.4 (CH2), 116.0 and 116.1 (CH), 117.5 (C), 121.3 (C), 124.0 and 124.3 (CH x 2), 124.1 (C), 141.0 (C 
x 2), 141.5 (C), 144.3 (C), 170.8 (C). Anal. Calcd. for C21H22O4: C 74.54%; H 6.55%. Found: C 
74.67%; H 6.35%. 
 
5.1.1.7. 4-Methyl-11-(4-bromobutyl)-1-oxo-3(H)-isobenzofuro[5,6-b][1,4]benzodioxine (5a). A 
mixture of the diene 11d (3.8 g, 11.7 mmol) and the lactone was treated following the general procedure 
to prepare lactones as described above to obtain 5a. The crude product was purified by silica gel column 
chromatography, using hexane/ethyl acetate 90/10 as eluent to obtain the desired lactone 5a as a white 
solid in 31% yield (1.43 g, 3.62 mmol). The isomer 5b (2.08 g, 5.26 mmol) was obtained as a white 
solid in 43% yield using hexane/ethyl acetate 8/2. mp 146-148 ºC (hexane/dichloromethane). IR (KBr)  
(cm-1): 1754 (C=O), 1260 (Ar-O), 1032 (Ar-O), 751 (C-Br). 1H NMR (CDCl3, 200 MHz) (ppm): 1.64-
1.87 (m, 2H, CH2), 1.87-2.03 (m, 2H, CH2), 2.16 (s, 3H, CH3), 3.08 (t, J = 7.4 Hz, 2H, CH2), 3.47 (m, 
2H, CH2), 5.05 (s, 2H, CH2O), 6.87-6.95 (m, 4H, Ar). 
13C NMR (CDCl3, 50.3 MHz) (ppm): 10.8 
(CH3), 22.3 (CH2), 28.3 (CH2), 32.3 (CH2), 33.7 (CH2), 67.8 (CH2), 116.1 and 116.4 (CH), 117.1 and 
117.2 (C), 124.1 and 124.6 (CH), 128.0 (C), 140.5 and 140.8 (C), 141.3 and 142.2 (C), 144.8 (C), 170.4 
(C). Anal Calcd. for C19H17BrO4: C 58.63%; H 4.40%, Br 20.53%. Found: C 58.56%; H 4.34%, Br 
20.88%. 
 
5.1.1.8. 11-Methyl-4-(4-bromobutyl)-1-oxo-3(H)-isobenzofuro[5,6-b][1,4]benzodioxine (5b). 
Analytical data: mp 160-162 ºC (dichloromethane). IR (KBr)  (cm-1): 1753 (C=O), 1259 (Ar-O), 1025 
(C-O), 753 (C-Br). 1H NMR (CDCl3, 200 MHz) (ppm): 1.64-1.83 (m, 2H, CH2), 1.85-2.04 (m, 2H, 
CH2), 2.54 (s, 3H, CH3), 2.59 (t, J = 7.4 Hz, 2H, CH2), 3.47 (t, J = 6.0 Hz, 2H, CH2Br), 5.10 (s, 2H, 
CH2O), 6.87-6.98 (m, 4H, Ar). 
13C NMR (CDCl3, 50.3 MHz) (ppm): 9.4 (CH3), 24.8 (CH3), 27.3 
(CH2), 31.9 (CH2), 33.1 (CH2), 67.5 (CH2), 116.1 and 116.4 (CH), 117.7 (C), 120.3 (C), 122.6 (C), 
123.9 and 124.5 (CH), 124.6 (C), 140.7 and 141.0 (C), 141.4 (C), 144.4 (C), 170.8 (C). Anal. Calcd. for 
C19H17BrO4:C 58.63%; H 4.40%, Br 20.53%. Found: C 58.77%; H 4.56%, Br 20.77%. 
 
5.1.1.9. 11-Hexyl-4-methyl-1-oxo-3(H)-isobenzothiofeno5,6-b1,4benzodioxine (6a). A mixture of 
the diene 11c (4 g, 14.7 mmol) and the thiolactone was treated following the general procedure to 
prepare lactones as described above to obtain 6a. The crude product was purified by silica gel column 
chromatography, using as eluent hexane/ethyl acetate 80/20 to obtain the desired lactone as a white solid 
in 39% yield (2.065 g, 5.73 mmol). The isomer 6b (2.44 g, 6.76 mmol) was obtained using hexane/ethyl 
acetate 70/30 as a white solid in 46% yield. mp 126-129 ºC (ethyl acetate). IR (KBr)  (cm-1): 2928 (C-
H), 1670 (C=O), 1265 (Ar-O), 1100 (C-O). 1H NMR (CDCl3, 200 MHz) (ppm): 0.85-0.98 (m, 3H, 
CH3), 1.25-1.57 (m, 6H, (CH2)3), 1.55-1.60 (m, 2H, CH2), 2.21 (s, 3H, CH3), 3.10 (t, J = 7.5 Hz, 2H, 
CH2), 4.16 (s, 2H, CH2S), 6.90-6.96 (m, 4H, Ar). 
13C NMR (CDCl3, 50.3 MHz) (ppm): 10.4 (CH3), 
14.4 (CH3), 22.9 (CH2), 23.2 (CH2), 29.5 (CH2), 30.1 (CH2), 32.0 (CH2), 32.1 (CH2), 116.3 and 116.4 
(CH), 119.6 (C), 123.9 and 124.5 (CH), 127.3 (C), 128.3 (C), 140.0 (C), 141.3 and 141.6 (C), 143.4 (C), 
197.0 (C). Anal. Calc. for C21H22O3S: C 71.16%; H 6.26%. Found: C 70.99%; H 6.45%. 
 
5.1.1.10. 4-Hexyl-11-methyl-1-oxo-3(H)-isobenzothiofeno[5,6-b][1,4]benzodioxine (6b). Analytical 
data of 6b: mp 131-133 ºC (ethyl acetate). IR (KBr)  (cm-1): 2926 (C-H), 1678 (C=O), 1268 (Ar-O). 
1H NMR (CDCl3, 200 MHz) (ppm): 0.86-0.93 (m, 3H, CH3), 1.21-1.40 (m, 6H, (CH2)3), 1.46-1.66 (m, 
2H, CH2), 2.56 (s, 3H, CH3C11), 2.66 (t, J = 7.5 Hz, 2H, CH2), 4.23 (s, 2H, CH2S), 6.69-6.98 (m, 4H, 
Ar). 13C NMR (CDCl3, 50.3 MHz) (ppm): 9.8 (CH3), 14.1 (CH3,), 22.7 (CH2), 26.0 (CH2), 29.0 (CH2), 
29.5 (CH2), 29.8 (CH2), 31.7 (CH2), 116.3 and 116.5 (CH), 123.3 (C), 123.8 and 124.5 (CH), 124.6 (C), 
128.0 (C), 140.1 and 141.2 (C), 141.7 and 142.8 (C), 143.7 (C), 197.5 (C). Anal. Calcd. for C21H22O3S: 
C 71.16%; H 6.26%. Found: C 71.33%; H 6.44%. 
 
5.1.1.11. 4-Methyl-8-methoxy-11-pentyl-1-oxo-3(H)-isobenzofuro[5,6-b][1,4]benzodioxine (7a).  A 
mixture of the diene 11f (3.2 g, 11.11 mmol) and the lactone was treated following the general 
procedure to prepare lactones as described above to obtain 7a. The crude product was purified by silica 
gel column chromatography, using hexane/ethyl acetate 99/1 as eluent to obtain the desired lactone as a 
white solid in 37% of yield (1.523 g, 4.11 mmol). The isomer 7b (1.98 g, 5.33 mmol) was obtained with 
hexane/ethyl acetate 98/2 as a white solid in 45% yield. Analytical data for 7a: mp 137-139 ºC 
(hexane/ethyl acetate). IR (KBr)  (cm-1): 1754 (C=O), 1260 (Ar-O), 1126 (C-O). 1H NMR (CDCl3, 
200 MHz) (ppm): 0.83-0.88 (m, 3H, CH3), 1.30-1.41 (m, 4H, (CH2)2), 1.47-1.66 (m, 2H, CH2), 2.15 
(s, 3H, CH3Ar), 3.03 (t, J = 7.5 Hz, 2H, CH2), 3.76 (s, 3H, CH3O), 5.06 (s, 2H, CH2O), 6.42-6.48 (m, 
2H, C1H, C7H), 6.48 (s, 1H, C9H), 6.78-6.85 (m, 1H, C6H). 13C NMR (CDCl2, 50.3 MHz) (ppm): 
10.8 (CH3), 14.2 (CH3), 22.6 (CH2), 23.4 (CH2), 29.8 (CH2), 31.6 (CH2), 55.9 (CH3), 67.7 (CH2), 102.3 
(CH), 108.7 (CH), 116.5 (CH), 116.4 (C), 117.0 (C), 129.2 (C), 134.9 (C), 140.2 (C), 142.0 (C), 142.2 
(C), 145.0 (C), 156.2 (C), 170.4 (C). Anal. Calcd. for C22H24O5: C 71.72%; H 6.57%. Found: C 71.98%; 
H 6.65%. 
 
5.1.1.12. 11-Methyl-7-methoxy-4-pentyl-1-oxo-3(H)-isobenzofuro[5,6-b][1,4]benzodioxine (7b). 
Analytical data: mp 117-119 ºC (ethyl acetate). IR (KBr)  (cm-1): 1750 (C=O), 1260 (Ar-O), 1030 (C-
O). 1H NMR (CDCl3, 200 MHz) (ppm): 0.80-0.93 (m, 3H, CH3), 1.20-1.39 (m, 4H, (CH2)2), 1.40-1.65 
(m, 2H, CH2), 2.54 (s, 3H, CH3C11), 2.55 (t, J = 7.5 Hz, 2H, CH2), 3.80 (s, 3H, CH3O), 5.12 (s, 2H, 
CH2O), 6.41-6.52 (m, 1H, C8H), 6.49 (s, 1H, C6H), 6.82-6.85 (m, 1H, C9H). 
13C NMR (CDCl3, 50.3 
MHz) (ppm): 9.5 (CH3), 14.1 (CH3), 22.3 (CH2), 26.0 (CH2), 28.4 (CH2), 31.5 (CH2), 55.9 (CH3), 67.7 
(CH2), 102.4 (CH), 108.9 (CH), 116.4 (CH), 117.9 (C), 121.6 (C), 124.2 (C), 135.5 (C), 141.3, 141.4, 
and 141.5 (C), 144.0 (C), 155.9 (C), 171.1 (C). Anal. Calcd. for C21H22O5: C 71.17%; H 6.26%. Found: 
C 71.87%; H 6.35%. 
 
5.2. Biological Experimental 
 
5.2.1. L1210 Inhibition Growth Rate Determination. L1210 leukemia cells were grown in RPMI 
1640 medium, supplemented with 2 mM of L-glutamine, 200 IU/mL of penicillin, 50 g/mL of 
streptomycin and 20% heat inactivated horse serum. They were incubated at 37 ºC in a 5% CO2 
atmosphere. The tested compounds studied were dissolved in DMSO (0.5% of final incubation volume) 
and added to the exponential growth phase cells seeded at an initial concentration of 0.8 x 105 cells/mL. 
After 48 h, the cells were counted in triplicate using a Coultronics Coulter Counter and the results were 
expressed as the compound concentration, which inhibited cell growth by 50% as compared to the 
control (IC50). The IC50 values were calculated from regression lines obtained from the probit of the 
percent cell growth inhibition plotted as a function of the logarithm of the dose. 
 
5.2.2. Inhibition of Cellular Proliferation and Cell Cycle Effects [26]. L1210 leukemia cells were 
grown in RPMI 1640 medium supplemented with 2 mM of L-glutamine, 200 IU/mL of penicillium, 50 
g/mL of streptomycin, and 20% heat inactivated horse serum. The cells were incubated for 21 h at 37 
ºC in a 5% CO2 atmosphere and incubated with an appropriate compound concentration range. Cells 
were then fixed by ethanol (70% v/v), then washed, and incubated with PBS containing 100 M of 
RNAse and 25 M/mL of propidium iodide for 30 min at room temperature. For each concentration, 104 
cells were analyzed using a flow cytometer (Beckman Coulter). Results were expressed as a percentage 
of cells accumulated in each phase of the cell cycle and are indicated. 
 
 
5.2.3. Cell culture [26]. HT29 human colorectal adenocarcinoma cells were cultured in 10 mL RPMI 
1640 medium supplemented with fetal bovine serum, L-glutamine and sodium pyruvate. Cells were 
maintained at 37 °C in a humidified atmosphere of 95% air and 5% CO2, or under hypoxic conditions 
(0.1% O2, 94.9% N2, 5% CO2) in a Whitley H35 Hypoxia-station (Don Whitley Scientific, Shipley, 
UK). 
In addition, seeded into 96-well plates at a density of 1.8 x 103 cells per well for chemosensitivity 
studies. Next day, compounds were added to the cells in an appropriate concentration and incubated for 
24 hours. After this, media was removed and cells were washed once with 100 µL of PBS and replaced 
with 200 µL of fresh medium. In case of the hypoxic investigations both PBS and medium were 
incubated at least 24 hours under hypoxic conditions to ensure appropriate O2 level was reached all 
cytotoxic drug stock solutions were prepared in DMSO, fractioned and stored at -20 °C. Drug 
concentrations were prepared with complete RPMI immediately before use and the final concentration 
of DMSO did not exceed 0.1% (v/v). Chemosensitivity was carried out using the MTT assay as 
previously described (5.2.1). 
 
5.2.4. OIDD Lilly Tests 
 KRas inhibition studies and antiangiogenesis activities (performed at Lilly) were performed as described in the 
procedures indicated in the OIDD-Lilly program (Open Innovation Drug Discovery, Eli Lilly) 
(https://openinnovation.lilly.com). 
 
5.3. Molecular modeling methods 
Calculations were obtained with the AMBER v.14 software package [27] using the PMEMD program 
(CPU and GPU versions).  The ff14SB [28] force field was used for the protein and the gaff [29] one for 
the ligand. Force field parameters for GTP were obtained from Meagher et al [30] and the 3D structure 
of the Kras protein was obtained from the Protein Data Bank server (PDB) with ID code 4DSN [31].  
Bond orders and protonation states of the protein were automatically adjusted by using the protein 
preparation wizard workflow included in the Maestro v.10.0 software package [32]. The 
phosphomethylphosphonic acid guanylate ester (GCP) cofactor was manually modified to be 
transformed into the guanosine triphosphate cofactor (GTP). 
 
5.3.1. Docking of Compound 2a (L2a) 
The docking of compound 2a (L2a) was done using Schrodinger’s Glide software [33] with the 
standard-precision (SP) docking mode. The ligand was prepared with the The LigPrep module of 
Maestro with default options, and a flexible ligand sampling was done. The same process was repeated 
for the five pockets identified in ref. [23]. Figure 3 shows pockets one to four, while pocket p3a is 
located between loops L5 and L7 and helix 5, very close to pocket p3. The five best docked poses for 
each pocket ranked by the GlideScore energy function were saved for further studies [34]. 
 
 
5.3.2. Study of Compound 2a-OCH3 
Starting from the last snapshot of the L2a molecular dynamics trajectory, a methoxy group was 
introduced manually as a substituent of the first aromatic ring of the tetracyclic lactone (at C-7 position) 
to compare its stability with respect to the original 2a ligand. Next, 100 ns of molecular dynamics were 
conducted keeping the ligand structure fixed in order to adapt the protein to the new ligand. Then, 900 
ns with no restraints were done in order to achieve convergence along the time in the ΔGb values. To 
have the same molecular dynamics length for both compounds, the molecular dynamics of the L2a 
system was also extended to 900 ns. 
 
 
5.3.3. Molecular dynamics (MD) simulations 
All the KRas-L2a complexes were prepared using the same protocol. The LEaP module of Ambertools 
v.16 [35] was used to create a cubic box of TIP3P [36] waters with a minimum distance between any 
atom of the system and the edge of the box of 15 Å and removing water molecules closer than 2.2 Å to 
any of the complex atoms. Next, the system was neutralized with counterions following a grid-shaped 
procedure for mapping electrostatic potential surface. Finally, the ParmEd program was used to produce 
hydrogen mass repartitioning to allow an integration time of 4 fs [37]. The prepared structures were 
heated to 300 K during 200 ps at a constant rate of 30 K/20 ps with harmonic restrains of 1 kcal mol-1 Å-
2 in the protein main atoms. Next, 400 ps at constant pressure were performed to increase the system 
density using harmonic restrains of 1 kcal mol-1 Å-2 in the protein main atoms. Finally, different 
production molecular dynamic simulations were done under the canonical ensemble using a Langevin 
[38] thermostat with a collision frequency of 3 ps-1 for temperature control. Long-range electrostatic 
energy was computed using the Particle Mesh Ewald summation method [39] with a cutoff of 9 Å for 
non-bonded interactions. SHAKE algorithm [40] was used to constrain the bonds involving the 




5.3.4. MMPB/GBSA Calculations 
 
The binding free energy, ΔGbind, for all the studied protein-ligand systems was evaluated using the 
MMGB/PBSA (molecular mechanics generalized Born/ Poisson Boltzmann surface area) methods as 
implemented in the MMPBSA.py module of Ambertools v.16 [35]. In  this approach, the total binding 
free energy is calculated as ΔGbinding = ΔH
0
gas – TΔS
0 + ΔGsolv, where ΔH
0
gas, the gas phase interaction 
energy, is calculated as the sum of the internal energy (ΔH0int) and two non-bonded terms corresponding 
to the van der Waals (ΔH0vdW) and electrostatic (ΔH
0





+ ΔH0vdW + ΔH
0
elec. The solvation free energy (ΔGsolv) is obtained by summing the polar (ΔGpolar) and 
nonpolar (ΔGnonpolar) terms: ΔGsolv= ΔGpolar + ΔGnonpolar. For the MMGBSA method the ΔGpolar is 
calculated using the Onufriev-Bashford-Case (OBC) generalized Born [41] (igb=2) whereas the 
nonpolar contribution (ΔGnonpolar) is calculated from the solvent accessible surface area (SASA) 
according to the equation: ΔGnonpolar = γ SASA + β where the values for γ and β were set to 0.0072 kcal 
mol-1 Å-2 and 0 kcal mol-1 [42]. On the other hand, for the MMPBSA method the ΔGpolar is calculated 
using the  Poisson Boltzmann approach while the nonpolar contribution (ΔGnonpolar) is obtained using γ = 
0.00542 kcal mol-1 Å-2 and β = 0.92 kcal mol-1 [43]. In both methods, values for interior and exterior 
dielectric constants were set to 1 and 80, respectively. In order to assess the convergence and stability of 
the Gbind values along the time, MMPB/GBSA computations were performed for the complete MD 
simulations using 100 structures each nanosecond, extracted each 10 ps, using the cpptraj program as 
implemented in Ambertools v.16 [35]. The contribution of each KRas residue to the total binding free 
energy was obtained using the MMGBSA decomposition method [44]. 
 
 
Supporting Information Available: (see footnote on the first page of this article): Additional Molecular studies 
data of new compounds. This material is available free of charge via the internet at http://dx.doi.org/ejmech 
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